Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Optimal SARS-CoV-2 vaccine allocation using real-time seroprevalence estimates in Rhode Island and Massachusetts

Thu Nguyen-Anh Tran, Nathan Wikle, Joseph Albert, Haider Inam, Emily Strong, Karel Brinda, Scott M Leighow, Fuhan Yang, Sajid Hossain, Justin R Pritchard, Philip Chan, William P Hanage, Ephraim M Hanks, Maciej F Boni
doi: https://doi.org/10.1101/2021.01.12.21249694
Thu Nguyen-Anh Tran
1Center for Infectious Disease Dynamics, Department of Biology, Pennsylvania State University, University Park, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan Wikle
2Center for Infectious Disease Dynamics, Department of Statistics, Pennsylvania State University, University Park, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Albert
3Department of Physics, Pennsylvania State University, University Park, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haider Inam
4Center for Infectious Disease Dynamics, Department of Bioengineering, Pennsylvania State University, University Park, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily Strong
2Center for Infectious Disease Dynamics, Department of Statistics, Pennsylvania State University, University Park, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karel Brinda
5Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA
6Department of Biomedical Informatics, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott M Leighow
4Center for Infectious Disease Dynamics, Department of Bioengineering, Pennsylvania State University, University Park, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fuhan Yang
1Center for Infectious Disease Dynamics, Department of Biology, Pennsylvania State University, University Park, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sajid Hossain
7Yale School of Medicine, Yale University, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justin R Pritchard
4Center for Infectious Disease Dynamics, Department of Bioengineering, Pennsylvania State University, University Park, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip Chan
8Department of Medicine, Brown University, Providence, RI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William P Hanage
5Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ephraim M Hanks
2Center for Infectious Disease Dynamics, Department of Statistics, Pennsylvania State University, University Park, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maciej F Boni
1Center for Infectious Disease Dynamics, Department of Biology, Pennsylvania State University, University Park, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mfb9@psu.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

As three SARS-CoV-2 vaccines come to market in Europe and North America in the winter of 2020-2021, distribution networks will be in a race against a major epidemiological wave of SARS-CoV-2 that began in autumn 2020. Rapid and optimized vaccine allocation is critical during this time. With 95% efficacy reported for two of the vaccines, near-term public health needs require that distribution is prioritized to the elderly, health-care workers, teachers, essential workers, and individuals with co-morbidities putting them at risk of severe clinical progression. Here, we evaluate various age-based vaccine distributions using a validated mathematical model based on current epidemic trends in Rhode Island and Massachusetts. We allow for varying waning efficacy of vaccine-induced immunity, as this has not yet been measured. We account for the fact that known COVID-positive cases may not be included in the first round of vaccination. And, we account for current age-specific immune patterns in both states. We find that allocating a substantial proportion (> 75%) of vaccine supply to individuals over the age of 70 is optimal in terms of reducing total cumulative deaths through mid-2021. As we do not explicitly model other high mortality groups, this result on vaccine allocation applies to all groups at high risk of mortality if infected. Our analysis confirms that for an easily transmissible respiratory virus, allocating a large majority of vaccinations to groups with the highest mortality risk is optimal. Our analysis assumes that health systems during winter 2020-2021 have equal staffing and capacity to previous phases of the SARS-CoV-2 epidemic; we do not consider the effects of understaffed hospitals or unvaccinated medical staff. Vaccinating only seronegative individuals avoids redundancy in vaccine use on individuals that may already be immune, and will result in 1% to 2% reductions in cumulative hospitalizations and deaths by mid-2021. Assuming high vaccination coverage (> 28%) and no major relaxations in distancing, masking, gathering size, or hygiene guidelines between now and spring 2021, our model predicts that a combination of vaccination and population immunity will lead to low or near-zero transmission levels by the second quarter of 2021.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

MFB, TNAT are funded by a grant from the Bill and Melinda Gates Foundation (INV-005517). FY is supported by the NIH/NIAID Center of Excellence in Influenza Research and Surveillance contract HHS N272201400007C. KB was partially supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number R35GM133700. WPH is funded by an award from the NIGMS (U54 GM088558). JA is funded by the Penn State MRSEC, Center for Nanoscale Science, NSF DMR-1420620. EH was partially supported by NSF DMS-2015273.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

None needed. Study is a mathematical modeling evaluation of vaccine prioritization based on publicly available COVID-19 data.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data and code are available at https://github.com/bonilab/covid19-vaccine-allocation-RI-MA

https://github.com/bonilab/covid19-vaccine-allocation-RI-MA

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted January 15, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Optimal SARS-CoV-2 vaccine allocation using real-time seroprevalence estimates in Rhode Island and Massachusetts
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Optimal SARS-CoV-2 vaccine allocation using real-time seroprevalence estimates in Rhode Island and Massachusetts
Thu Nguyen-Anh Tran, Nathan Wikle, Joseph Albert, Haider Inam, Emily Strong, Karel Brinda, Scott M Leighow, Fuhan Yang, Sajid Hossain, Justin R Pritchard, Philip Chan, William P Hanage, Ephraim M Hanks, Maciej F Boni
medRxiv 2021.01.12.21249694; doi: https://doi.org/10.1101/2021.01.12.21249694
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Optimal SARS-CoV-2 vaccine allocation using real-time seroprevalence estimates in Rhode Island and Massachusetts
Thu Nguyen-Anh Tran, Nathan Wikle, Joseph Albert, Haider Inam, Emily Strong, Karel Brinda, Scott M Leighow, Fuhan Yang, Sajid Hossain, Justin R Pritchard, Philip Chan, William P Hanage, Ephraim M Hanks, Maciej F Boni
medRxiv 2021.01.12.21249694; doi: https://doi.org/10.1101/2021.01.12.21249694

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (500)
  • Anesthesia (110)
  • Cardiovascular Medicine (1226)
  • Dentistry and Oral Medicine (205)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (528)
  • Epidemiology (9999)
  • Forensic Medicine (5)
  • Gastroenterology (497)
  • Genetic and Genomic Medicine (2442)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1634)
  • Health Policy (750)
  • Health Systems and Quality Improvement (633)
  • Hematology (247)
  • HIV/AIDS (530)
  • Infectious Diseases (except HIV/AIDS) (11855)
  • Intensive Care and Critical Care Medicine (625)
  • Medical Education (251)
  • Medical Ethics (74)
  • Nephrology (267)
  • Neurology (2272)
  • Nursing (139)
  • Nutrition (349)
  • Obstetrics and Gynecology (451)
  • Occupational and Environmental Health (532)
  • Oncology (1244)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (154)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (729)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (281)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4823)
  • Radiology and Imaging (833)
  • Rehabilitation Medicine and Physical Therapy (488)
  • Respiratory Medicine (650)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (224)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (124)
  • Urology (99)